SRI secures $14.3m service contracts from NCI
The research company will receive $11.7m for toxicology studies and an additional $2.6 m for pharmacology and pharmacokinetics studies which will be conducted through NCI’s Developmental Therapeutics Program.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.